People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Deep Blue Medical Advances, Inc. | — | Biotechnology | Series A | $18.1M | $15.6M | 2020 |
| CerSci Therapeutics Inc. | — | Pharmaceuticals | Series A | $12.0M | $371.7M | 2019 |
Brent Duncan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brent Duncan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John D. Harkey, Jr. | 1 | 5 |
| David Genecov | 1 | 4 |
| Ken Gall | 1 | 4 |
| Michael Bates | 1 | 3 |
| Perry Molinoff | 1 | 3 |
| William Perry | 1 | 3 |
| Tyler Brous | 1 | 3 |
| Robert Bonczek | 1 | 3 |
| Neil Meyer | 1 | 2 |
| Robert Isaacs | 1 | 2 |
| Pat Confalone | 1 | 1 |
| Lucas Rodriguez | 1 | 1 |
| David Hitt II | 1 | 1 |
| Scott Dax | 1 | 1 |
| Dennis Robbins | 1 | 1 |
| Howard Levinson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.